[{"id":"be70552b-91c6-47c2-8ebb-321b354e1717","acronym":"","url":"https://clinicaltrials.gov/study/NCT04700319","created_at":"2021-01-19T20:50:20.104Z","updated_at":"2024-07-02T16:36:33.644Z","phase":"Phase 1","brief_title":"CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies","source_id_and_acronym":"NCT04700319","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19/CD20 CAR T-cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/19/2019","start_date":" 04/19/2019","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2021-03-08"}]